Home>>Signaling Pathways>> Others>>Clodronate (sodium salt hydrate)

Clodronate (sodium salt hydrate) (Synonyms: Clodronic acid)

Catalog No.GC43279

Clodronate (sodium salt hydrate) (Disodium clodronate tetrahydrate) is first-generation bisphosphonate, with anti-osteoporotic, anti-inflammatory and analgesic effects.

Products are for research use only. Not for human use. We do not sell to patients.

Clodronate (sodium salt hydrate) Chemical Structure

Cas No.: 88416-50-6

Size Price Stock Qty
5mg
$21.00
In stock
10mg
$36.00
In stock
50mg
$45.00
In stock
100mg
$72.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Bisphosphonates bind strongly to bone and reduce bone resorption through effects on both osteoclasts and osteoblasts. Clodronate is a non-nitrogenous bisphosphonate that has been used in the treatment of osteoporosis and other metabolic bone diseases. It binds to hydroxyapatite crystals with an affinity constant of 0.72 µM, inhibiting their growth (IC50 = 1.34 µM) and bone resorption. Clondronate is metabolized intracellularly to a β-γ-methylene analog of ATP that is cytotoxic to both osteoclasts and macrophages, which belong to the same cell lineage as osteoclasts. Liposome-encapsulated bisphosphonates such as clodronate have been used in biological research to selectively deplete macrophage-like cells and cancer cells.

Reviews

Review for Clodronate (sodium salt hydrate)

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Clodronate (sodium salt hydrate)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.